Yiyao Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yiyao Xu has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Haitao Zhao
Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
10 shared publications Junwei Zhang
Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS and PUMC), Beijing, China
8 shared publicationsHanchun Huang
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 shared publicationsJin Bian
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 shared publicationsXin Lu
Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
7 shared publicationsAnqiang Wang
Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Liver Surg, 1 Shuaifuyuan, Beijing 100730, Peoples R China
5 shared publications
Latest Publications
- Open Access
- 9 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1159885
Case Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two cases
Hepatocellular carcinoma (HCC) is often diagnosed at an unresectable stage without opportunities for curative therapy. Future liver remnant (FLR) insufficiency limits the range of patients who can undergo radical resection. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) can ultimately achieve short-term hypertrophy of the FLR in patients with viral hepatitis-related fibrosis/cirrhosis and R0 resection. However, the influence of immune checkpoint inhibitors (ICIs) on liver regeneration remains unknown. We report two patients diagnosed with Barcelona Clinic Liver Cancer (BCLC)-B stage hepatitis B virus (HBV)-related HCC who underwent pioneering ALPPS after immunotherapy without posthepatectomy liver failure (PHLF). ALPPS has been shown to be safe and feasible in patients with HCC who underwent immunotherapy previously for the first time and might provide an alternative salvage option for future conversion therapy of HCC.
- 9 May 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1159885
Open AccessCase Report: The application of associating liver partition and portal vein ligation for staged hepatectomy in patients with hepatitis b virus-related hepatocellular carcinoma after undergoing treatment with an immune checkpoint inhibitor: a report of two cases
Hepatocellular carcinoma (HCC) is often diagnosed at an unresectable stage without opportunities for curative therapy. Future liver remnant (FLR) insufficiency limits the range of patients who can undergo radical resection. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) can ultimately achieve short-term hypertrophy of the FLR in patients with viral hepatitis-related fibrosis/cirrhosis and R0 resection. However, the influence of immune checkpoint inhibitors (ICIs) on liver regeneration remains unknown. We report two patients diagnosed with Barcelona Clinic Liver Cancer (BCLC)-B stage hepatitis B virus (HBV)-related HCC who underwent pioneering ALPPS after immunotherapy without posthepatectomy liver failure (PHLF). ALPPS has been shown to be safe and feasible in patients with HCC who underwent immunotherapy previously for the first time and might provide an alternative salvage option for future conversion therapy of HCC.
- 1 March 2023
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 158 (3) , 325-327
Treatment for Patients With Multifocal Intrahepatic Cholangiocarcinoma
To the Editor We read the study by Franssen et al with great interest. The authors showed that the overall survival after hepatic arterial infusion pump (HAIP)
- 1 March 2023
- Published by American Medical Association (AMA) in JAMA Surgery
- Vol. 158 (3) , 325-327
Treatment for Patients With Multifocal Intrahepatic Cholangiocarcinoma
To the Editor We read the study by Franssen et al with great interest. The authors showed that the overall survival after hepatic arterial infusion pump (HAIP)
- Open Access
- 11 October 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 982972
Diagnosis and treatment of liver metastases of parathyroid carcinoma
Introduction: Parathyroid carcinoma (PC) is a very rare endocrine malignancy occurring in less than 1% of all cases of primary hyperparathyroidism (pHPT). The liver is the second most common target organ for distant metastases of PC, but no guidelines are available for the diagnosis and treatment of liver metastases. In this study, we attempted to summarize the characteristics of the diagnosis and treatment of liver metastases based on our patients and other cases reported in the literature.Materials and methods: The files of all patients diagnosed with PC with liver metastases summarized at our center between 2000 and 2022 were reviewed, and three datasets from Medline, Web of Science, and Embase were systematically searched to identify relevant articles.Results: Three patients with liver metastases from our center and 11 patients from the literature were included in the study. All patients had pHPT with borderline remission of hypercalcemia after each operation. A total of 71.4% of the patients’ liver lesions were found by abdominal CT scans, while 35.7% were found by MRI, PET-CT, and fine-needle aspiration biopsy (FNAB), which were also helpful for diagnosis. Eight of nine patients (88.9%) who underwent surgery, radiofrequency ablation (RFA), or transcatheter arterial embolization (TAE) were alive, and only one postoperative patient died after a follow-up of 60 months.Conclusions: PC is a rare malignant tumor prone to recurrence and metastasis, and postoperative reviews should be carried out routinely. Abnormally elevated parathyroid hormone (PTH) and serum calcium can indicate recurrence or metastasis. Enhanced CT and MRI can provide valuable support for the diagnosis of liver metastases, but whether [18F]FDG-PET-CT, [18F]FCH-PET-CT, or [11C]choline-PET-CT can be used as a diagnostic basis requires further study. Resection of liver metastases, segmental hepatectomy, or RFA can significantly improve patients’ symptoms.
- 11 October 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 982972
Open AccessDiagnosis and treatment of liver metastases of parathyroid carcinoma
Introduction: Parathyroid carcinoma (PC) is a very rare endocrine malignancy occurring in less than 1% of all cases of primary hyperparathyroidism (pHPT). The liver is the second most common target organ for distant metastases of PC, but no guidelines are available for the diagnosis and treatment of liver metastases. In this study, we attempted to summarize the characteristics of the diagnosis and treatment of liver metastases based on our patients and other cases reported in the literature.Materials and methods: The files of all patients diagnosed with PC with liver metastases summarized at our center between 2000 and 2022 were reviewed, and three datasets from Medline, Web of Science, and Embase were systematically searched to identify relevant articles.Results: Three patients with liver metastases from our center and 11 patients from the literature were included in the study. All patients had pHPT with borderline remission of hypercalcemia after each operation. A total of 71.4% of the patients’ liver lesions were found by abdominal CT scans, while 35.7% were found by MRI, PET-CT, and fine-needle aspiration biopsy (FNAB), which were also helpful for diagnosis. Eight of nine patients (88.9%) who underwent surgery, radiofrequency ablation (RFA), or transcatheter arterial embolization (TAE) were alive, and only one postoperative patient died after a follow-up of 60 months.Conclusions: PC is a rare malignant tumor prone to recurrence and metastasis, and postoperative reviews should be carried out routinely. Abnormally elevated parathyroid hormone (PTH) and serum calcium can indicate recurrence or metastasis. Enhanced CT and MRI can provide valuable support for the diagnosis of liver metastases, but whether [18F]FDG-PET-CT, [18F]FCH-PET-CT, or [11C]choline-PET-CT can be used as a diagnostic basis requires further study. Resection of liver metastases, segmental hepatectomy, or RFA can significantly improve patients’ symptoms.
- 16 September 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 118 (1) , 18
Pleomorphic Hyalinizing Angiectatic Tumor in the Upper Abdomen
An abstract is unavailable. This article is available as a PDF only.
- 16 September 2022
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 118 (1) , 18
Pleomorphic Hyalinizing Angiectatic Tumor in the Upper Abdomen
An abstract is unavailable. This article is available as a PDF only.
- 1 July 2022
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 103, 106648
Evolution of associating liver partition and portal vein ligation for staged hepatectomy from 2012 to 2021: A bibliometric analysis. Review
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has become increasingly popular during the past few decades, and its indications have extended from patients with normal liver to post-chemotherapy patients and even patients with cirrhosis. However, few studies have assessed the publications in relation to ALPPS. Web of Science was searched to identify studies related to ALPPS published from 2012 to 2021. The analysis was performed using the bibliometric package (Version 3.1.0) in R software. In total, 486 publications were found. These articles were published in 159 journals and authored by 2157 researchers from 694 organizations. The most prolific journal was Annals of Surgery (24 articles and 1170 citations). The most frequently cited article was published in Annals of Surgery (average citations, 72.7; total citations, 727). China was the most productive country for ALPPS publications but had comparatively less interaction with other countries. Both thematic evolution and co-occurrence network analysis showed low numbers of topics such as failure, resection, and safety among the publications but large numbers of highly cited papers on outcomes, prediction, mechanisms, multicenter analysis, and novel procedures such as liver venous deprivation. A total of 196 studies focused the clinical application of ALPPS, and most studies were IDEAL Stages I and II. The specific mechanism of ALPPS liver regeneration remains unclear. This is the first bibliometric analysis offering an overview of the development of ALPPS research publications. Our findings identified prominent studies, countries, institutions, journals, and authors to indicate the future direction of ALPPS research. The role of ALPPS in liver regeneration and the long-term results of ALPPS need further study. Future research directions include comparison of ALPPS with portal vein embolization, liver venous deprivation, and other two-stage hepatectomies as well as patients' quality of life after ALPPS.
- 1 July 2022
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 103, 106648
Evolution of associating liver partition and portal vein ligation for staged hepatectomy from 2012 to 2021: A bibliometric analysis. Review
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) has become increasingly popular during the past few decades, and its indications have extended from patients with normal liver to post-chemotherapy patients and even patients with cirrhosis. However, few studies have assessed the publications in relation to ALPPS. Web of Science was searched to identify studies related to ALPPS published from 2012 to 2021. The analysis was performed using the bibliometric package (Version 3.1.0) in R software. In total, 486 publications were found. These articles were published in 159 journals and authored by 2157 researchers from 694 organizations. The most prolific journal was Annals of Surgery (24 articles and 1170 citations). The most frequently cited article was published in Annals of Surgery (average citations, 72.7; total citations, 727). China was the most productive country for ALPPS publications but had comparatively less interaction with other countries. Both thematic evolution and co-occurrence network analysis showed low numbers of topics such as failure, resection, and safety among the publications but large numbers of highly cited papers on outcomes, prediction, mechanisms, multicenter analysis, and novel procedures such as liver venous deprivation. A total of 196 studies focused the clinical application of ALPPS, and most studies were IDEAL Stages I and II. The specific mechanism of ALPPS liver regeneration remains unclear. This is the first bibliometric analysis offering an overview of the development of ALPPS research publications. Our findings identified prominent studies, countries, institutions, journals, and authors to indicate the future direction of ALPPS research. The role of ALPPS in liver regeneration and the long-term results of ALPPS need further study. Future research directions include comparison of ALPPS with portal vein embolization, liver venous deprivation, and other two-stage hepatectomies as well as patients' quality of life after ALPPS.
- Open Access
- 1 June 2022
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 11 (3) , 495-497
Development and internal validation of the Comprehensive ALPPS Preoperative Risk Assessment (CAPRA) score
Development and internal validation of the Comprehensive ALPPS Preoperative Risk Assessment (CAPRA) score
- 1 June 2022
- Published by AME Publishing Company in HepatoBiliary Surgery and Nutrition
- Vol. 11 (3) , 495-497
Open AccessDevelopment and internal validation of the Comprehensive ALPPS Preoperative Risk Assessment (CAPRA) score
Development and internal validation of the Comprehensive ALPPS Preoperative Risk Assessment (CAPRA) score
- 16 November 2021
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 276 (6) , e1115-e1116
Comment on: “Liver Venous Deprivation or Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy? A Retrospective Multicentric Study”: How to Choose a Way to Enhance the Growth of Future Liver Remnant in the Future
An abstract is unavailable. This article is available as a PDF only.
- 16 November 2021
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 276 (6) , e1115-e1116
Comment on: “Liver Venous Deprivation or Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy? A Retrospective Multicentric Study”: How to Choose a Way to Enhance the Growth of Future Liver Remnant in the Future
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 October 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (19) , 1246
Safety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows radical resection of colorectal liver metastasis (CRLM). However, the effect of ALPPS on hepatocellular carcinoma (HCC) is not completely understood. This systematic review aimed to examine the existing data on the safety, feasibility, and oncologic effect of ALPPS on HCC. Electronic databases, including PubMed, Web of Science, and Embase, were systemically searched to identify articles on ALPPS and HCC. Additional articles were identified manually. The feasibility (liver hypertrophy between two stages), safety (90-day mortality), and therapeutic effect (long-term survival) were analyzed. Nine published articles that satisfied the retrieval standards were included, and these studies involved 176 patients. The evidence level of the enrolled studies was low, among which, the greatest Oxford evidence level was 2c. Additionally, the average median increase in future liver volume was 178 mL, the average interval between two stages was 11.2 days, the interval was remarkably longer in radiofrequency-assisted ALPPS (RALPPS) patients (28 days), and the average 90-day mortality was 17.6% (range, 0–50%). However, the oncological outcomes were not well documented. Survival following ALPPS was evidently improved compared with that after transcatheter arterial chemoembolization (TACE). This value was comparable to that following the one-stage hepatectomy and portal vein embolization (PVE), and it was similar to that in CRLM patients over the long term. Publication biases caused by case series and single-center reports are common in the review. It is concluded in this review that ALPPS is a safe and feasible approach to treat selected patients with unresectable HCC, but its oncological outcome requires further study. RALPPS is not recommended for HCC patients because of the long waiting time between the two stages.
- 1 October 2020
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 8 (19) , 1246
Open AccessSafety, feasibility, and efficacy of associating liver partition and portal vein ligation for staged hepatectomy in treating hepatocellular carcinoma: a systematic review
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows radical resection of colorectal liver metastasis (CRLM). However, the effect of ALPPS on hepatocellular carcinoma (HCC) is not completely understood. This systematic review aimed to examine the existing data on the safety, feasibility, and oncologic effect of ALPPS on HCC. Electronic databases, including PubMed, Web of Science, and Embase, were systemically searched to identify articles on ALPPS and HCC. Additional articles were identified manually. The feasibility (liver hypertrophy between two stages), safety (90-day mortality), and therapeutic effect (long-term survival) were analyzed. Nine published articles that satisfied the retrieval standards were included, and these studies involved 176 patients. The evidence level of the enrolled studies was low, among which, the greatest Oxford evidence level was 2c. Additionally, the average median increase in future liver volume was 178 mL, the average interval between two stages was 11.2 days, the interval was remarkably longer in radiofrequency-assisted ALPPS (RALPPS) patients (28 days), and the average 90-day mortality was 17.6% (range, 0–50%). However, the oncological outcomes were not well documented. Survival following ALPPS was evidently improved compared with that after transcatheter arterial chemoembolization (TACE). This value was comparable to that following the one-stage hepatectomy and portal vein embolization (PVE), and it was similar to that in CRLM patients over the long term. Publication biases caused by case series and single-center reports are common in the review. It is concluded in this review that ALPPS is a safe and feasible approach to treat selected patients with unresectable HCC, but its oncological outcome requires further study. RALPPS is not recommended for HCC patients because of the long waiting time between the two stages.
- Open Access
- 1 December 2019
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 7 (23) , 795
Acute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: two case reports and a literature review
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is used for avoiding postoperative live failure caused by insufficient future liver remnant (FLR) after major liver resection. However, ALPPS accompanied by high morbidity and mortality. The surgeons focus their attention mainly on the common complications such as bile leak, bleeding, infection and liver failure. Acute kidney injury (AKI) is a relatively rare postoperative complication, and get less attention. However, once AKI occurred after the surgery, it will seriously affect the prognosis of patients. We firstly report two cases of postoperative AKI after ALPPS in hepatocellular carcinoma with liver cirrhosis. Case 1, a 61-year-old male, chief complaint upper abdominal pain for half a month, medical examination found a huge liver space-occupying lesion. The clinical diagnosis was liver cancer, and ALPPS was performed. After the first step of surgery, delayed renal replacement therapy (RRT) was initiated when stage 3 AKI diagnosed. Although the second step surgery completed successfully, the patient eventually died of multiple organ dysfunction syndrome (MODS) induced by gastrointestinal bleeding. Case 2, a 64-year-old male chief complaint right liver mass present to our hospital, with a small FLR. Stage 2 AKI was diagnosed after the first step of ALPPS, early RRT was started immediately. Renal function gradually recovered, and the second step surgery was completed. The patient discharged with a good condition, found no recurrence in the latest follow-up. ALPPS for hepatocellular carcinoma with liver cirrhosis cases, more likely to happen AKI. More strict patient screening criteria, early RRT may improve the prognosis.
- 1 December 2019
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 7 (23) , 795
Open AccessAcute kidney injury after associating liver partition and portal vein ligation for staged hepatectomy for hepatocellular carcinoma: two case reports and a literature review
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is used for avoiding postoperative live failure caused by insufficient future liver remnant (FLR) after major liver resection. However, ALPPS accompanied by high morbidity and mortality. The surgeons focus their attention mainly on the common complications such as bile leak, bleeding, infection and liver failure. Acute kidney injury (AKI) is a relatively rare postoperative complication, and get less attention. However, once AKI occurred after the surgery, it will seriously affect the prognosis of patients. We firstly report two cases of postoperative AKI after ALPPS in hepatocellular carcinoma with liver cirrhosis. Case 1, a 61-year-old male, chief complaint upper abdominal pain for half a month, medical examination found a huge liver space-occupying lesion. The clinical diagnosis was liver cancer, and ALPPS was performed. After the first step of surgery, delayed renal replacement therapy (RRT) was initiated when stage 3 AKI diagnosed. Although the second step surgery completed successfully, the patient eventually died of multiple organ dysfunction syndrome (MODS) induced by gastrointestinal bleeding. Case 2, a 64-year-old male chief complaint right liver mass present to our hospital, with a small FLR. Stage 2 AKI was diagnosed after the first step of ALPPS, early RRT was started immediately. Renal function gradually recovered, and the second step surgery was completed. The patient discharged with a good condition, found no recurrence in the latest follow-up. ALPPS for hepatocellular carcinoma with liver cirrhosis cases, more likely to happen AKI. More strict patient screening criteria, early RRT may improve the prognosis.